TKIs for CML work by binding to the adenosine triphosphate (ATP) site of the BCR::ABL1 oncoprotein to inhibit aberrant kinase activity (5, 6). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.